Sunshine Biopharma (NASDAQ:SBFM) Issues Quarterly Earnings Results

Sunshine Biopharma (NASDAQ:SBFM) released its quarterly earnings results on Wednesday. The company reported ($0.25) EPS for the quarter, Zacks reports. Sunshine Biopharma had a negative return on equity of 27.14% and a negative net margin of 17.86%.

Sunshine Biopharma Price Performance

Shares of NASDAQ SBFM opened at $0.66 on Thursday. The company has a market cap of $3.24 million, a P/E ratio of -0.45 and a beta of 1.37. Sunshine Biopharma has a 1 year low of $0.66 and a 1 year high of $2.43. The firm has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.26.

Institutional Trading of Sunshine Biopharma

Several institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in Sunshine Biopharma in the fourth quarter worth about $29,000. Citadel Advisors LLC lifted its stake in Sunshine Biopharma by 23.1% in the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after purchasing an additional 14,656 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in Sunshine Biopharma in the third quarter worth about $32,000. Institutional investors own 41.98% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sunshine Biopharma in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.00.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.